Roy Baynes, Merck Research Laboratories CMO (file photo)
FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough
A few months ago, Merck emerged as a clear leader among a group of drugmakers racing through the clinic with a new class of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
